AbbVie's Menstrual Migraine Treatment Meets Primary, Secondary Endpoints in Phase 3 Trial
By Kelly Cloonan
AbbVie said its migraine drug met the primary and secondary endpoints in a phase 3 trial evaluating it for preventive treatment of menstrual migraines.
The company on Thursday said the study showed that its atogepant treatment reduced migraine days by 1.2 days on average versus 0.4 days with a placebo.
Atogepant also demonstrated statistically significant and clinically meaningful improvements versus placebo across measures of headache burden, acute medication use, functional disability and cognitive function, the company said.
AbbVie said it plans to submit the data to health authorities worldwide and present findings at future medical congresses.
The company said there are no treatment options currently approved for menstrual migraine.
"Menstrual migraine attacks can be severe, long lasting and disruptive to daily life. These data bring us closer to our goal of bringing a potential treatment option for women living with this debilitating disease," said Primal Kaur, senior vice president, global development of immunology, neuroscience, eye care and specialty at AbbVie.
Atogepant is an orally-administered drug used to prevent migraine headaches. It is marketed as Qulipta in the U.S., Canada, Israel and Puerto Rico, and as Aquipta in the EU. It is approved in 60 countries.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
September 10, 2026 09:53 ET (13:53 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States